Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies

A Blauvelt; C Paul; P van de Kerkhof; RB Warren; AB Gottlieb; RG Langley; F Brock; C Arendt; M Boehnlein; M Lebwohl; K Reich

A Blauvelt

Oregon Medical Research Center, Portland, OR

C Paul

Paul Sabatier University, Toulouse

P van de Kerkhof

Radboud University, Nijmegen

RB Warren

Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester

AB Gottlieb

Icahn School of Medicine at Mount Sinai, New York, NY

RG Langley

Dalhousie University, Nova Scotia

F Brock

UCB Pharma, Slough

C Arendt

UCB Pharma, Brussels

M Boehnlein

UCB Pharma, Monheim

M Lebwohl

Icahn School of Medicine at Mount Sinai, New York, NY

K Reich

Centre for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf Skinflammation? Center, Hamburg

Keywords

Psoriasis, Certolizumab

Abstract

Abstract not available.

References

1. Certolizumab Pegol Prescribing Information. Available at www.accessdata.fda.gov/scripts/cder/daf/index.cfm;
2. Certolizumab Pegol Summary of Product Characteristics. Available at www.ema.europa.eu/ema;
3. Blauvelt A et al. JEADV 2019;33(suppl 3):21–2;
4. Gisondi P et al. Int J Mol Sci 2017;18:2427.

Poster PDF

Published

Jan 28, 2020

How to Cite

Blauvelt, A., Paul, C., van de Kerkhof, P., Warren, R., Gottlieb, A., Langley, R., Brock, F., Arendt, C., Boehnlein, M., Lebwohl, M., & Reich, K. (2020). Long-Term Safety of Certolizumab Pegol in Plaque Psoriasis: Pooled Analysis over 3 Years from Three Phase 3, Randomized, Placebo-Controlled Studies. SKIN The Journal of Cutaneous Medicine, 4(1), S5. Retrieved from https://jofskin.org/33014/index.php/skin/article/view/809

Issue

Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)

Section

Poster Presentations at 2020 Winter Clinical Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

RB Warren, C Conrad, P Foley, L Iversen, RG Langley, G Kokolakis, L Davis, V Vanvoorden, S Wiegratz, JF Merola, Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
KA Papp, M Lebwohl, AB Gottlieb, M Sebastian, R Langley, Y Okubo, M Wang, C Cioffi, F Staelens, K Reich, Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
RB Warren, A Blauvelt, J Bagel, KA Papp, P Yamauchi, A Armstrong, R Langley, V Vanvoorden, D De Cuyper, L Peterson, N Cross, K Reich, Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE) , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
K Reich, K Papp, A Blauvelt, R Langley, A Armstrong, RB Warren, K Gordon, JF Merola, C Madden, M Wang, V Vanvoorden, M Lebwohl, Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
C.E.M. Griffiths, K.A. Papp, M Song, M Miller, Y You, Y-K Shen, C Han, A Blauvelt, Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
K Reich, A Blauvelt, M Lebwohl, KA Papp, P Rich, B Strober, D De Cuyper, C Madden, L Peterson, V Vanvoorden, RB Warren, Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
CEM Griffiths, KA Papp, M Song, B Randazzo, S Li, YK Shen, C Han, A Blauvelt, Maintenance of Response With Guselkumab for up to 3 Years’ Treatment in the Phase 3 VOYAGE 1 Trial of Patients With Plaque Psoriasis , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters & Abstracts Presented at 2018 Fall Clinical Dermatology Conference®-Las Vegas
PCM van de Kerkhof, K Reich, CL Leonardi, A Blauvelt, NN Mehta, TF Tsai, R You, P Papanastasiou, M Milutinovic, CEM Griffiths, Secukinumab's Pooled and Long-Term Safety: Analysis of 19 Psoriasis Clinical Trials Up to 5 Years of Treatment , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
K Gordon, P Foley, JG Krueger, A Pinter, K Reich, R Vender, V Vanvoorden, C Madden, L Peterson, A Blauvelt, Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
M Lebwohl, M Siegel, L Shankle, L Pisenti, M Yassine, S Van Vorhees, A Comprehensive Survey Assessing the Family Planning Needs of Women with Psoriasis , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters & Abstracts Presented at 2018 Fall Clinical Dermatology Conference®-Las Vegas

1 2 3 4 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)